Lever
Lifestyle
- Regular cardiovascular exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
NT-proBNP
N-terminal pro-BNP · NT-pro-B-type Natriuretic Peptide · BNP
Herzmarker
- Einheit:
- pg/mL
NT-proBNP quantifies the level of N-terminal pro-B-type natriuretic peptide, a by-product of proBNP cleavage, reflecting cardiac stress.
Reference Ranges
Reference
0–125pg/mL
0
125
LowNormalHigh
Reference
Unit · pg/mLLevels increase with age; higher in females and those with renal impairment.
Overview
Übersicht
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker derived from the cleavage of proBNP, a precursor of B-type natriuretic peptide (BNP). It is released by cardiac myocytes in response to ventricular volume expansion and pressure overload. Researchers have found NT-proBNP to be a critical marker in the assessment of heart failure (HF), providing diagnostic and prognostic information. Clinically, NT-proBNP is essential in diagnosing acute decompensated heart failure (ADHF) and in differentiating between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). It is also used to monitor treatment efficacy, particularly in patients receiving angiotensin receptor-neprilysin inhibitors (ARNI). In the context of athletic performance and biohacking, NT-proBNP may not directly correlate with enhanced performance or longevity. However, it can be a useful marker for assessing cardiac stress and potential underlying cardiac conditions that could impact long-term health. Researchers observed that NT-proBNP levels can be influenced by factors such as age, renal function, and obesity, which may confound its interpretation. Therefore, it is crucial to consider these factors when evaluating NT-proBNP levels. Additionally, NT-proBNP does not require fasting and is not significantly affected by the time of day, making it a convenient marker for clinical use.
Klinische Bedeutung
Elevated NT-proBNP levels indicate cardiac stress, often associated with heart failure, and can predict adverse cardiovascular outcomes. Reduced levels are generally considered normal but may need interpretation in the context of clinical symptoms.
Dynamics
Trend Interpretation
Rising Values
Progressively rising NT-proBNP levels suggest worsening cardiac function or heart failure. Retest in 4-6 weeks if levels are outside the optimal range.
Falling Values
Falling levels may indicate improvement in cardiac function or effective treatment response.
Re-test Interval
4-6 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Heart failure
- Renal impairment
- Advanced age
- Pulmonary hypertension
- Acute coronary syndrome
Cause
Low Levels
- Normal cardiac function
- Effective heart failure treatment
- Younger age
- Lower body mass index
- Absence of cardiac stress
Protocol
How to Optimize
Lever
Nutrition
- Low-sodium diet
- Increased fruit and vegetable intake
Note:
Consult a healthcare provider before making significant lifestyle changes, especially in the presence of heart disease.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Every 6-12 months for heart failure patients, or as clinically indicated.
Interfering Factors
- Renal function
- Obesity
- Age
Related Peptides & Hormones
Bnp
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that while NT-proBNP is a valuable biomarker in heart failure, its diagnostic specificity in heart failure with preserved ejection fraction (HFpEF) remains debated due to confounding factors like age and renal function. Researchers have not yet established optimal reference ranges for NT-proBNP across diverse populations, particularly in sub-phenotyping cardiac patients. Additionally, clinical questions about the integration of NT-proBNP with emerging biomarkers for improved prognostic accuracy in various cardiac conditions remain unanswered.
30 Research Publications
265
Total Citations
12
Human/RCT
2.0
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
N-Terminal B-type Natriuretic Peptide in Heart Failure.
ReviewInfluence1.0
59
Researchers found that NT-proBNP is a guideline-mandated biomarker for heart failure (HF) and is particularly effective in diagnosing acute decompensated HF. The study highlighted its prognostic value, offering information independent of standard clinical predictors and refining risk stratification in HF patients.
02Top
#02
Evidence based application of BNP/NT-proBNP testing in heart failure.
ReviewInfluence2.0
50
This review summarized evidence on the application of BNP and NT-proBNP testing in heart failure. Researchers highlighted the importance of these biomarkers in diagnosing heart failure and discussed their potential roles in prognosis and therapy guidance.
03Top
#03
NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.
Meta-AnalysisInfluence6.0
34
Researchers conducted a systematic review to evaluate NT-proBNP levels in COPD patients. They found that NT-proBNP levels were significantly higher in patients with acute exacerbations and those with severe COPD, indicating its potential role in assessing cardiovascular stress.
04
#04
Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis.
Meta-AnalysisInfluence2.0
32
This meta-analysis compared the diagnostic efficacy of BNP and NT-proBNP in detecting cardioembolic stroke. Researchers found that while BNP had superior sensitivity, NT-proBNP demonstrated higher specificity in distinguishing cardioembolic from non-cardioembolic strokes in adult ischemic stroke patients.
05
#05
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
ReviewInfluence1.0
20
Researchers reviewed the effects of angiotensin receptor-neprilysin inhibitor (ARNI) therapy on the natriuretic peptide axis, focusing on NT-proBNP. They found that ARNI therapy decreases NT-proBNP levels while maintaining its prognostic accuracy for cardiovascular outcomes.
06
#06
Biomarkers in Takayasu arteritis.
Wen Dan, et al. · International journal of cardiology · 2023
Review
16
This study examined the role of various biomarkers, including NT-proBNP, in patients with Takayasu arteritis (TA). Researchers found that these biomarkers are valuable for early diagnosis, evaluating disease activity, and guiding treatment options in TA. The combination of biomarker assays and imaging may enhance the accuracy of TA detection.
Key findings
- 01Researchers observed that Takayasu arteritis involves complex interactions between immune system components and inflammation.
- 02They identified several biomarkers, including cytokines and autoantibodies, that may help in understanding the disease.
- 03The study highlights the need for further research to clarify the role of these biomarkers in Takayasu arteritis.
07
#07
Standardization of cardiac markers.
Review
16
This review focused on the standardization of cardiac biomarkers, including NT-proBNP. Researchers highlighted the importance of developing reference materials and quality specifications for immunoassays to optimize the clinical use of these biomarkers.
08
#08
Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
Human
11
Researchers found that higher levels of NT-proBNP in patients with asymptomatic severe aortic stenosis were associated with higher event rates for adverse outcomes. However, the study suggested limited value for single measurements of NT-proBNP to guide the timing of transcatheter aortic valve replacement.
09
#09
High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.
HumanInfluence1.0
5
In the SPRINT study, researchers found that lower levels of NT-proBNP were associated with greater cognitive benefits from intensive blood pressure treatment. Higher NT-proBNP levels indicated a higher risk of mild cognitive impairment or probable dementia.
10
#10
The Indian Consensus Document on cardiac biomarker.
Review
5
This study examined the role of cardiac biomarkers in diagnosing and managing heart failure in India. Researchers found that biomarkers can indicate the presence and severity of congestive heart failure (CHF) and may provide clinical benefits compared to conventional assessments.
Clinical Trials (4)
4
Total Trials
1,131
Total Enrolled
Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure
NCT07460505NOT_YET_RECRUITING
Sponsor
National University Hospital, Singapore
Enrollment
328
Started
2026
Primary outcome
N-terminal pro-B-type natriuretic peptide (NT-pro BNP)
Heart FailureOSA - Obstructive Sleep Apnea
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
NCT06593327RECRUITING
Sponsor
University of Texas Southwestern Medical Center
Enrollment
300
Started
2025
Primary outcome
Incident Heart Failure or All-cause death
Type 2 DiabetesDiabetic CardiomyopathyHeart FailureCardiometabolic Diseases
SGLT2 for Heart Failure in CHD Patients
NCT05897489UNKNOWN
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
100
Started
2023
Primary outcome
To evaluate, on real-life data, the efficacy of iSGLT2 in patients with heart failure related to congenital heart disease as defined by improvement in NYHA class and/or change in NT-proBNP.
Heart Failure
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study
NCT04125966UNKNOWN
Sponsor
University of Aarhus
Enrollment
403
Started
2019
Primary outcome
Diagnostic performance of NT-proBNP for ruling out heart failure in atrial fibrillation patients
Atrial FibrillationHeart Failure
Publication Trend
Research publications about NT-proBNP over time
8totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer